Dimensional Fund Advisors LP Has $4.78 Million Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE)

Dimensional Fund Advisors LP boosted its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 10.7% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 2,898,377 shares of the biopharmaceutical company's stock after acquiring an additional 279,360 shares during the period. Dimensional Fund Advisors LP owned 2.54% of Fate Therapeutics worth $4,782,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. acquired a new stake in Fate Therapeutics during the 4th quarter worth $40,000. FPC Investment Advisory Inc. acquired a new position in shares of Fate Therapeutics in the 4th quarter valued at $44,000. Y Intercept Hong Kong Ltd acquired a new position in shares of Fate Therapeutics in the 4th quarter valued at $58,000. Intech Investment Management LLC grew its holdings in shares of Fate Therapeutics by 27.5% in the 4th quarter. Intech Investment Management LLC now owns 39,443 shares of the biopharmaceutical company's stock valued at $65,000 after buying an additional 8,497 shares during the period. Finally, SG Americas Securities LLC grew its holdings in shares of Fate Therapeutics by 30.6% in the 4th quarter. SG Americas Securities LLC now owns 44,874 shares of the biopharmaceutical company's stock valued at $74,000 after buying an additional 10,511 shares during the period. Institutional investors and hedge funds own 97.54% of the company's stock.

Analyst Upgrades and Downgrades

FATE has been the subject of several research analyst reports. Wells Fargo & Company decreased their price target on shares of Fate Therapeutics from $5.00 to $4.00 and set an "equal weight" rating for the company in a report on Thursday, March 6th. StockNews.com raised shares of Fate Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday. Needham & Company LLC reaffirmed a "hold" rating on shares of Fate Therapeutics in a research report on Wednesday. Barclays cut their price target on shares of Fate Therapeutics from $10.00 to $2.00 and set an "overweight" rating on the stock in a research report on Wednesday. Finally, Robert W. Baird cut their price target on shares of Fate Therapeutics from $5.00 to $4.00 and set a "neutral" rating on the stock in a research report on Wednesday. Eight equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $4.14.

Fate Therapeutics Stock Up 5.9%

Shares of FATE stock traded up $0.06 on Friday, reaching $1.07. The stock had a trading volume of 2,096,528 shares, compared to its average volume of 2,243,338. The firm's 50-day moving average is $1.01 and its two-hundred day moving average is $1.50. The firm has a market capitalization of $122.63 million, a price-to-earnings ratio of -0.65 and a beta of 2.32. Fate Therapeutics, Inc. has a 12 month low of $0.66 and a 12 month high of $5.92.

Fate Therapeutics (NASDAQ:FATE - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.32) EPS for the quarter, beating analysts' consensus estimates of ($0.39) by $0.07. Fate Therapeutics had a negative net margin of 1,325.43% and a negative return on equity of 45.88%. The business had revenue of $1.63 million for the quarter, compared to analyst estimates of $1.18 million. On average, sell-side analysts forecast that Fate Therapeutics, Inc. will post -1.63 earnings per share for the current fiscal year.

Fate Therapeutics Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.